Title: Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced
fibrosis or cirrhosis in a real-world setting in Taiwan
Version: 2 Date: 02 May 2021
Reviewer's report:
This study focuses on a real life treatment experience with SOF/VEL in chronic hepatitis C
infection. The peculiarity of this work is that it is based on a study completely conducted in
Asia. The results are in keeping with others published in Europe or derived from global real
life experiences. However, there are some aspects that need to be presented and discussed in
more detail.
The Authors say that only few patients were treated with the combination of SOF/VEL
plus  ribavirin. In order to contribute to the debate on the addition of ribavirin to SOF/VEL
combination in patients with cirrhosis, recommended by international guidelines in Europe, it
would be important to specify how many patients with Child Pugh-Turcotte classes (CTP) A or
B were included in this study.  Please, include this information in both text and Tables. Were
only CTP B treated with the addition of ribavirin, or not?
Were among patients who prematurely discontinued treatment or did not complete the post
treatment follow up, subjects receiving ribavirin? Was any dose adjustment of ribavirin
required? Are data on adherence available?
Title: Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced
fibrosis or cirrhosis in a real-world setting in Taiwan
Version: 2 Date: 02 May 2021
Reviewer's report:
This study focuses on a real life treatment experience with SOF/VEL in chronic hepatitis C
infection. The peculiarity of this work is that it is based on a study completely conducted in
Asia. The results are in keeping with others published in Europe or derived from global real
life experiences. However, there are some aspects that need to be presented and discussed in
more detail.
The Authors say that only few patients were treated with the combination of SOF/VEL
plus  ribavirin. In order to contribute to the debate on the addition of ribavirin to SOF/VEL
combination in patients with cirrhosis, recommended by international guidelines in Europe, it
would be important to specify how many patients with Child Pugh-Turcotte classes (CTP) A or
B were included in this study.  Please, include this information in both text and Tables. Were
only CTP B treated with the addition of ribavirin, or not?
Were among patients who prematurely discontinued treatment or did not complete the post
treatment follow up, subjects receiving ribavirin? Was any dose adjustment of ribavirin
required? Are data on adherence available?
Please review this paper.
user
Title: Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced
fibrosis or cirrhosis in a real-world setting in Taiwan
Version: 2 Date: 02 May 2021
Reviewer's report:
This study focuses on a real life treatment experience with SOF/VEL in chronic hepatitis C
infection. The peculiarity of this work is that it is based on a study completely conducted in
Asia. The results are in keeping with others published in Europe or derived from global real
life experiences. However, there are some aspects that need to be presented and discussed in
more detail.
The Authors say that only few patients were treated with the combination of SOF/VEL
plus  ribavirin. In order to contribute to the debate on the addition of ribavirin to SOF/VEL
combination in patients with cirrhosis, recommended by international guidelines in Europe, it
would be important to specify how many patients with Child Pugh-Turcotte classes (CTP) A or
B were included in this study.  Please, include this information in both text and Tables. Were
only CTP B treated with the addition of ribavirin, or not?
Were among patients who prematurely discontinued treatment or did not complete the post
treatment follow up, subjects receiving ribavirin? Was any dose adjustment of ribavirin
required? Are data on adherence available?
assistant